Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer.

ABSTRACT:

Background

Knowledge on immunosuppressive factors in the pathogenesis of endometrial cancer is scarce. The aim of this study was to assess Glycodelin (Gd) and its immunosuppressive isoform Glycodelin A (GdA) in endometrial cancer tissue and to analyze its impact on clinical and pathological features and patient outcome.

Methods

292 patients diagnosed and treated for endometrial cancer were included. Patient characteristics, histology and follow-up data were available. Gd and GdA was determined by immunohistochemistry and in situ hybridization was performed for Gd mRNA.

Results

Endometrial cancer shows intermediate (52.2%) or high (20.6%) expression for Gd in 72.8%, and GdA in 71.6% (intermediate 62.6%, high 9.0%) of all cases. The glycosylation dependent staining of GdA is tumour specific and correlates with the peptide-specific Gd staining though neither of the two is associated with estrogen receptor, progesterone receptor or clinic-pathological features. Also Gd protein positively correlates with Gd mRNA as quantified by in situ hybridization. Gd positive cases have a favourable prognosis (p?=?0.039), while GdA positive patients have a poor outcome (p?=?0.003). Cox-regression analysis proofed GdA to be an independent prognostic marker for patient survival (p?=?0.002), besides tumour stage, grade and the concomitant diagnosis of hypertension.

Conclusion

Gd and GdA are commonly expressed in endometrial cancer tissue and seem to be of relevance in tumourigenesis. They differ not only in glycosylation but also in their biological activity, since only GdA holds prognostic significance for a poor overall survival in endometrial cancer patients. This finding might be explained by GdAs immunosuppressive capacity.

SUBMITTER: Lenhard M 

PROVIDER: S-EPMC3898404 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature